Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

MIRA PHARMACEUTICALS Aktie

 >MIRA PHARMA Aktienkurs 
1.225 EUR    (Tradegate)
Ask: 1.25 EUR / 3191 Stück
Bid: 1.2 EUR / 3345 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
MIRA PHARMA Aktie über LYNX handeln
>MIRA PHARMA Performance
1 Woche: -1,2%
1 Monat: -10,6%
3 Monate: +12,9%
6 Monate: +16,1%
1 Jahr: -27,7%
laufendes Jahr: +3,8%
>MIRA PHARMACEUTICALS Aktie
Name:  MIRA PHARMACEUTICALS INC.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US60458C1045 / A3EQWL
Symbol/ Ticker:  K6S (Frankfurt) / MIRA (NASDAQ)
Kürzel:  FRA:K6S, ETR:K6S, K6S:GR, NASDAQ:MIRA
Index:  -
Webseite:  https://www.mirapharmaceu..
Profil:  Mira Pharmaceuticals Inc. operates in the biotechn..
>Volltext..
Marktkapitalisierung:  22.79 Mio. EUR
Unternehmenswert:  22.17 Mio. EUR
Umsatz:  -
EBITDA:  -6.72 Mio. EUR
Nettogewinn:  -6.63 Mio. EUR
Gewinn je Aktie:  -0.41 EUR
Schulden:  -
Liquide Mittel:  0.62 Mio. EUR
Operativer Cashflow:  -5.19 Mio. EUR
Bargeldquote:  2.45
Umsatzwachstum:  -
Gewinnwachstum:  44.77%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MIRA PHARMACEUTICALS, MIRA PHARMACEUTICAL, MIRA PHARMA
Letzte Datenerhebung:  24.08.25
>MIRA PHARMA Kennzahlen
Aktien/ Unternehmen:
Aktien: 19.07 Mio. St.
Frei handelbar: 75.17%
Rückkaufquote: -14.74%
Mitarbeiter: 5
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 1166.31%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 44.2
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -399.86%
Eigenkaprendite: -556.87%
>MIRA PHARMA Peer Group

Es sind 601 Aktien bekannt.
 
19.08.25 - 14:42
 MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage (Accesswire)
 
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. ......
12.08.25 - 14:42
 MIRA Pharmaceuticals′ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin (Accesswire)
 
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagon......
30.07.25 - 13:42
 MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study (Accesswire)
 
Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pa......
29.07.25 - 13:42
 MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain (Accesswire)
 
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end MIAMI, FLORID......
11.07.25 - 14:06
 MIRA Pharmaceuticals: MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition (Accesswire)
 
SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier......
03.07.25 - 14:06
 MIRA Pharmaceuticals: MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks (Accesswire)
 
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NA......
03.07.25 - 09:09
 MIRA Pharmaceuticals€ Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours (Benzinga)
 
MIRA Pharmaceuticals (NASDAQ: MIRA) shares soared 50.8% to $1.87 in after-hours trading on Wednesday after announcing promising results for their non-opioid pain drug, Mira-55, and plans for future development. read more...
30.06.25 - 14:06
 MIRA Pharmaceuticals: MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition (Accesswire)
 
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDA......
25.06.25 - 14:07
 MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects (Accesswire)
 
MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics fo......
18.06.25 - 14:42
 MIRA Pharmaceuticals′ Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology (Accesswire)
 
MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologi......
28.05.25 - 14:42
 MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program (Accesswire)
 
The company will engage in BIO One-on-One Partnering meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, ......
08.05.25 - 15:36
 MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 14:09
 MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review (Accesswire)
 
With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be tra......
23.04.25 - 16:30
 MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.04.25 - 14:06
 MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation (Accesswire)
 
MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologi......
16.04.25 - 14:06
 MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion (Accesswire)
 
Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals,......
01.04.25 - 14:18
 MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain (Accesswire)
 
MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsy......
24.03.25 - 13:00
 MIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.03.25 - 12:42
 MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development (Accesswire)
 
Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. MIAMI, FL / ACCESS Newswire ......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Unzufriedenheit ist die erste Stufe zum Fortschritt für den einzelnen wie für die Nation. - Oscar Wilde
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!